Companies / Healthcare
Intismeran Plus Keytruda Cuts Melanoma Recurrence Risk 42% in Phase 3, but Moderna Shares Close Down 17.6%
Detailed results from the 1,137-patient trial showed hazard ratios of 0.58 for recurrence or death and 0.62 for distant metastasis or death, yet the stock fell sharply after the data leaked.